Publications by authors named "Z A Massy"
The therapeutic benefit of the oral adsorbent drug AST-120 in chronic kidney disease (CKD) is related to an indoxyl sulfate (IS)-lowering action. Diabetes and dyslipidemia might worsen kidney damage in CKD. However, it is not known whether AST-120 influences lipid abnormalities as well as renal function in patients with CKD and diabetes.
View Article and Find Full Text PDFPre-emptive kidney transplantation (PKT) has long been considered the optimal treatment for patients with end-stage chronic kidney disease (CKD) seeking the most favourable long-term outcomes. However, the significant growth in transplant procedures over recent decades has led to a notable increase in wait-listed patients and a disproportionate demand for donor organs. This situation necessitates a re-evaluation of transplantation timing and the establishment of rational indications from both societal and clinical perspectives.
View Article and Find Full Text PDFBackground And Hypothesis: Cardiovascular diseases are a leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Acute kidney injury (AKI) has been increasingly recognized as a potential exacerbating factor for cardiovascular events in these patients. The CKD-REIN study aims to explore the relationship between AKI and the risk of major adverse cardiovascular events (MACE) in a cohort of CKD patients.
View Article and Find Full Text PDFArticle Synopsis
- People with chronic kidney disease (CKD) face a higher risk of cognitive impairment (CI), and this study investigates the link between anticholinergic medications and cognitive performance in CKD patients.
- The research involved a prospective cohort study of 3007 nephrology outpatients, where data on medication prescriptions and cognitive function were collected over five years.
- Findings revealed that over half of the participants were prescribed anticholinergic drugs, with those having a high anticholinergic burden more likely to experience cognitive impairment, particularly if they had a history of neurological disorders or were on multiple medications.
Article Synopsis
- Blood pressure (BP) control is crucial for preventing complications in chronic kidney disease (CKD), yet many patients struggle to reach target levels; this study evaluates how antihypertensive prescriptions change over time in CKD patients.
- Conducted with 2,755 hypertensive CKD patients in France, the study tracked factors influencing prescription changes, such as patient demographics and healthcare provider interactions.
- Results showed that over five years, there was a high rate of changes in medication; poor adherence to medications increased the likelihood of needing additional drugs, while having a lower education level led to more frequent withdrawals of antihypertensive medications.